Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01859455 · ClinicalTrials.gov registry record · Phase 1
Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT01859455 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 25 participants.
The verdict
NCT01859455, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of LGT209 in hypercholesterolemic patients taking common statin medications and in healthy volunteers.
Interventions
- DRUG Placebo
- DRUG LGT209 50 mg
- DRUG LGT209 300 mg
- DRUG Statins (atorvastatin or simvastatin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2011-07 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01859455
The ClinicalTrials.gov registry entry for NCT01859455 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01859455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01859455 about?
NCT01859455 is a clinical study titled "Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins". This study is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of LGT209 in hypercholesterolemic patients taking common statin medications and in healthy volunteers.
What is the current status of trial NCT01859455?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2011-07. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01859455?
The interventions under investigation include: Placebo (DRUG), LGT209 50 mg (DRUG), LGT209 300 mg (DRUG), Statins (atorvastatin or simvastatin) (DRUG).
Who is sponsoring clinical trial NCT01859455?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.